Evidence map›Paper›PMID 24917582›Full record

ArticleThe Journal of antimicrobial chemotherapy2014

Mechanisms of reduced susceptibility and genotypic prediction of antibiotic resistance in Prevotella isolated from cystic fibrosis (CF) and non-CF patients.

Laura J Sherrard, Bettina Schaible, Kathryn A Graham, Stef J McGrath, Leanne McIlreavey, Joseph Hatch, Matthew C Wolfgang, Marianne S Muhlebach, Deirdre F Gilpin, Thamarai Schneiders and 2 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Article
  3. Proteome level analysis of drug-resistantFrontiers in microbiology · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Microorganisms · 2021
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Laura J SherrardCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK School of Pharmacy, Queen's University Belfast, Belfast, UK l.sherrard@qub.ac.uk.
Bettina SchaibleCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK School of Pharmacy, Queen's University Belfast, Belfast, UK.
Kathryn A GrahamCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK School of Pharmacy, Queen's University Belfast, Belfast, UK.
Stef J McGrathCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK School of Pharmacy, Queen's University Belfast, Belfast, UK.
Leanne McIlreaveyCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK School of Pharmacy, Queen's University Belfast, Belfast, UK.
Joseph HatchCystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Matthew C WolfgangCystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Marianne S MuhlebachDepartment of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Deirdre F GilpinCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK School of Pharmacy, Queen's University Belfast, Belfast, UK.
Thamarai SchneidersCentre for Infection & Immunity, School of Medicine, Dentistry & Biomedical Science, Queen's University Belfast, Belfast, UK.
J Stuart ElbornCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK Centre for Infection & Immunity, School of Medicine, Dentistry & Biomedical Science, Queen's University Belfast, Belfast, UK.
Michael M TunneyCF & Airways Microbiology Group, Queen's University Belfast, Belfast, UK School of Pharmacy, Queen's University Belfast, Belfast, UK.
Queen's University Belfast · GBUniversity of North Carolina at Chapel Hill · US

Funding

The Mucus Transport Apparatus: Why Two Layers?P50HL084934 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2006 to 2010
$15.6M
The Role of Anaerobic Bacterial Infection in Cystic FibrosisR01HL092964 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BOUCHER, RICHARD CHARLES · 2010 to 2013
$2.9M
NHLBI NIH HHS HL084934NHLBI NIH HHS HL092964
6 · The paper itself

Abstract

objectivesTo investigate mechanisms of reduced susceptibility to commonly used antibiotics in Prevotella cultured from patients with cystic fibrosis (CF), patients with invasive infection and healthy control subjects and to determine whether genotype can be used to predict phenotypic resistance.

methodsThe susceptibility of 157 Prevotella isolates to seven antibiotics was compared, with detection of resistance genes (cfxA-type gene, ermF and tetQ), mutations within the CfxA-type β-lactamase and expression of efflux pumps.

resultsPrevotella isolates positive for a cfxA-type gene had higher MICs of amoxicillin and ceftazidime compared with isolates negative for this gene (P < 0.001). A mutation within the CfxA-type β-lactamase (Y239D) was associated with ceftazidime resistance (P = 0.011). The UK CF isolates were 5.3-fold, 2.7-fold and 5.7-fold more likely to harbour ermF compared with the US CF, UK invasive and UK healthy control isolates, respectively. Higher concentrations of azithromycin (P < 0.001) and clindamycin (P < 0.001) were also required to inhibit the growth of the ermF-positive isolates compared with ermF-negative isolates. Furthermore, tetQ-positive Prevotella isolates had higher MICs of tetracycline (P = 0.001) and doxycycline (P < 0.001) compared with tetQ-negative isolates. Prevotella spp. were also shown, for the first time, to express resistance nodulation division (RND)-type efflux pumps.

conclusionsThis study has demonstrated that Prevotella isolated from various sources harbour a common pool of resistance genes and possess RND-type efflux pumps, which may contribute to tetracycline resistance. The findings indicate that antibiotic resistance is common in Prevotella spp., but the genotypic traits investigated do not reflect phenotypic antibiotic resistance in every instance.

Indexed as

GenotypeAmino Acid SubstitutionAnti-Bacterial AgentsBacteroidaceae Infectionsbeta-LactamasesCase-Control StudiesCeftazidimeCephalosporin ResistanceCystic FibrosisDrug Resistance, MicrobialGenes, BacterialHumansMicrobial Sensitivity TestsMutationPrevotellaTetracyclineAnti-Bacterial Agentsbeta-LactamasesCeftazidimeTetracyclineefflux pumpsresistance genesβ-lactamases

Identifiers

PMID24917582
PMCPMC4164140
OpenAlexW2154663142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.